Sanofi

SNYNASDAQHealthcare● Active

$45.02

+$0.64(+1.44%)

Market Cap$108.4B

P/E Ratio—

52W High$52.68

52W Low$42.28

Avg Volume3.0M

Open$45.00

Beta0.28

Free Cash Flow Financials Revenue

Sanofi (SNY) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

SNY · free cash flow · updated Jun 8, 2026

Core FCF metrics

SNY · FCF · TTM · margin & CAGR

Free cash flow was $10.14B for FY2025 (fiscal year ending 2025-12-31), up 72.3% year-over-year The FCF margin was 21.7%. Five-year CAGR stands at +13.7%.

FY2025 Free Cash Flow$10.14B▲ +72.3% YoY

Trailing 12M (TTM)$8.28Btrailing 4 quarters sum

FCF Margin21.7%$10.14B ÷ revenue

3-Year CAGR+6.8%FY2022 → FY2025

5-Year CAGR+13.7%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

SNY · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$12.13B(1.99B)$10.14B▲ +72.3%21.7%

FY2024$9.08B(3.19B)$5.89B▼ 31.9%13.3%

FY2023$10.26B(1.62B)$8.64B▲ +3.8%20.8%

FY2022$10.53B(2.20B)$8.32B▼ 1.8%20.5%

FY2021$10.52B(2.04B)$8.48B▲ +58.9%21.6%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

SNY · P/FCF · FCF yield · FCF per share

Sanofi (SNY) trades at a FCF yield of 20.27% and a price-to-free-cash-flow ratio of 13.3x. FCF per share stands at $3.39, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

20.27%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$3.39

TTM FCF ÷ Shares Outstanding

Price / FCF

x13.3

Share Price ÷ FCF per Share

EV / FCF (TTM)

x5.7

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

SNY · cash flow statement · operating / investing / financing

For FY2025, Sanofi generated $12.13B in operating cash flow and spent 1.99B in capital expenditures, yielding $10.14B in free cash flow.

Operating Activities

+$12.13B

Cash from core business operations

2025-12-31

Investing Activities

−$2.76B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$9.26B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($12.13B) − |CapEx| (1.99B) = FCF ($10.14B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

SNY vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

SanofiYOU

SNY

$10.14B+72.3%21.7%

51%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Sanofi (SNY) reported free cash flow of $10.14B for FY2025 (fiscal year ending 2025-12-31), up 72.3% year-over-year. The FCF margin was 21.7%.

Based on available data, Sanofi has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $10.14B in FY2025. The 5-year CAGR stands at +13.7%.

Sanofi's FCF yield is 20.27% and price-to-FCF ratio is 13.3x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

SNY free cash flow · 8 questions

Sanofi free cash flow was $10.14B for FY2025, up 72.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $8.28B.

SNY free cash flowSNY FCFSNY FCF 2025SNY free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Sanofi · Sanofi SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026